Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017101623> ?p ?o ?g. }
- W2017101623 endingPage "763" @default.
- W2017101623 startingPage "753" @default.
- W2017101623 abstract "Introduction: In preliminary clinical studies, aleglitazar, a new dual PPAR-α–γ agonist, has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. This review will provide up-to-date information on the clinical safety and efficacy of aleglitazar, which is currently under Phase III clinical investigation for reduction of cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome. Areas covered: A PubMed literature search (January 1950 to February 2011) was conducted using the following search terms: aleglitazar, PPAR, PPAR α agonist, PPAR γ agonist and PPAR α/γ agonist. Additional articles were gathered using reference lists from sources obtained from the original literature search. This review summarizes available information pertaining to pharmacodynamics, pharmacokinetics, clinical studies and safety/tolerability of aleglitazar. The effects of this new drug are compared and contrasted with those of fibrates (PPAR-α agonists), thiazolidinediones (PPAR-γ agonists) and other dual PPAR-α–γ agonists. Expert opinion: Preliminary evidence from clinical studies with aleglitazar is promising, with reported improvements in glycemia, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglycerides, apolipoprotein B and blood pressure. However, PPAR-α- and -γ-associated side effects have been observed and additional large-scale, long-term clinical studies are necessary to better understand the clinical implications of these effects." @default.
- W2017101623 created "2016-06-24" @default.
- W2017101623 creator A5016390787 @default.
- W2017101623 creator A5080379883 @default.
- W2017101623 creator A5089581104 @default.
- W2017101623 date "2011-04-27" @default.
- W2017101623 modified "2023-10-16" @default.
- W2017101623 title "Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk" @default.
- W2017101623 cites W172609984 @default.
- W2017101623 cites W1830151520 @default.
- W2017101623 cites W1969437387 @default.
- W2017101623 cites W1971175832 @default.
- W2017101623 cites W1987941106 @default.
- W2017101623 cites W1992153775 @default.
- W2017101623 cites W1997416444 @default.
- W2017101623 cites W2003602721 @default.
- W2017101623 cites W2007003907 @default.
- W2017101623 cites W2007582789 @default.
- W2017101623 cites W2033204507 @default.
- W2017101623 cites W2039592725 @default.
- W2017101623 cites W2044064793 @default.
- W2017101623 cites W2046335747 @default.
- W2017101623 cites W2062551263 @default.
- W2017101623 cites W2063065419 @default.
- W2017101623 cites W2068817437 @default.
- W2017101623 cites W2076733877 @default.
- W2017101623 cites W2082680963 @default.
- W2017101623 cites W2084060595 @default.
- W2017101623 cites W2086602774 @default.
- W2017101623 cites W2088725333 @default.
- W2017101623 cites W2090460655 @default.
- W2017101623 cites W2095236486 @default.
- W2017101623 cites W2102675827 @default.
- W2017101623 cites W2102906564 @default.
- W2017101623 cites W2104359225 @default.
- W2017101623 cites W2112234259 @default.
- W2017101623 cites W2117205405 @default.
- W2017101623 cites W2119528634 @default.
- W2017101623 cites W2120312841 @default.
- W2017101623 cites W2120822075 @default.
- W2017101623 cites W2127125241 @default.
- W2017101623 cites W2131490500 @default.
- W2017101623 cites W2144125787 @default.
- W2017101623 cites W215860509 @default.
- W2017101623 cites W2159969745 @default.
- W2017101623 cites W2163521556 @default.
- W2017101623 cites W2164324917 @default.
- W2017101623 cites W2166180770 @default.
- W2017101623 cites W2166834443 @default.
- W2017101623 cites W2181092548 @default.
- W2017101623 cites W2182460401 @default.
- W2017101623 cites W2188846692 @default.
- W2017101623 cites W2198678228 @default.
- W2017101623 cites W2596624061 @default.
- W2017101623 cites W2786398486 @default.
- W2017101623 cites W4247041730 @default.
- W2017101623 doi "https://doi.org/10.1517/17425255.2011.579561" @default.
- W2017101623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21521130" @default.
- W2017101623 hasPublicationYear "2011" @default.
- W2017101623 type Work @default.
- W2017101623 sameAs 2017101623 @default.
- W2017101623 citedByCount "23" @default.
- W2017101623 countsByYear W20171016232012 @default.
- W2017101623 countsByYear W20171016232013 @default.
- W2017101623 countsByYear W20171016232014 @default.
- W2017101623 countsByYear W20171016232015 @default.
- W2017101623 countsByYear W20171016232016 @default.
- W2017101623 countsByYear W20171016232017 @default.
- W2017101623 countsByYear W20171016232019 @default.
- W2017101623 crossrefType "journal-article" @default.
- W2017101623 hasAuthorship W2017101623A5016390787 @default.
- W2017101623 hasAuthorship W2017101623A5080379883 @default.
- W2017101623 hasAuthorship W2017101623A5089581104 @default.
- W2017101623 hasConcept C126322002 @default.
- W2017101623 hasConcept C134018914 @default.
- W2017101623 hasConcept C170493617 @default.
- W2017101623 hasConcept C197934379 @default.
- W2017101623 hasConcept C2777180221 @default.
- W2017101623 hasConcept C2778096610 @default.
- W2017101623 hasConcept C2778375690 @default.
- W2017101623 hasConcept C2778938600 @default.
- W2017101623 hasConcept C555293320 @default.
- W2017101623 hasConcept C60644358 @default.
- W2017101623 hasConcept C71924100 @default.
- W2017101623 hasConcept C7341990 @default.
- W2017101623 hasConcept C86803240 @default.
- W2017101623 hasConcept C98274493 @default.
- W2017101623 hasConceptScore W2017101623C126322002 @default.
- W2017101623 hasConceptScore W2017101623C134018914 @default.
- W2017101623 hasConceptScore W2017101623C170493617 @default.
- W2017101623 hasConceptScore W2017101623C197934379 @default.
- W2017101623 hasConceptScore W2017101623C2777180221 @default.
- W2017101623 hasConceptScore W2017101623C2778096610 @default.
- W2017101623 hasConceptScore W2017101623C2778375690 @default.
- W2017101623 hasConceptScore W2017101623C2778938600 @default.
- W2017101623 hasConceptScore W2017101623C555293320 @default.
- W2017101623 hasConceptScore W2017101623C60644358 @default.
- W2017101623 hasConceptScore W2017101623C71924100 @default.